Lu Si
Impact in
- Oncology top 0.5%
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- Molecular Biology top 5%
- Melanoma and MAPK Pathways
- Circular RNAs in diseases
Papers in
- Oncology 85
- Cutaneous Melanoma Detection and Management 44
- Cancer Immunotherapy and Biomarkers 35
-
- Melanoma and MAPK Pathways 35
- Co-authors
- Jun Guo (80 shared papers)Xinan Sheng (93 shared papers)Chuanliang Cui (86 shared papers)Zhihong Chi (85 shared papers)Lili Mao (64 shared papers)Yan Kong (48 shared papers)Jie Dai (53 shared papers)Bin Lian (59 shared papers)
- Journals
- Annals of Oncology (15 papers)European Journal of Cancer (14 papers)Clinical Cancer Research (10 papers)BMC Cancer (8 papers)Frontiers in Oncology (6 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Lu Si
205 papers receiving 6.0k citations
Lu Si's Hit Papers
Peers
Comparison fields: 5 of 78
- Oncology 2.2k
- Molecular Biology 1.1k
- Cancer Research 185
- Ophthalmology 102
- Pulmonary and Respiratory Medicine 258
Countries citing papers authored by Lu Si
This map shows the geographic impact of Lu Si's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Si with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Si more than expected).
Fields of papers citing papers by Lu Si
This network shows the impact of papers produced by Lu Si. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Si. The network helps show where Lu Si may publish in the future.
Co-authors
The 25 scholars most cited alongside Lu Si, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 212 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 561 | |
| 2 | 2011 | 305 | |
| 3 | 2019 | 243 | |
| 4 | Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Hit paper breakdown → | 2020 | 241 |
| 5 | 2011 | 208 | |
| 6 | 2011 | 206 | |
| 7 | 2018 | 163 | |
| 8 | 2019 | 149 | |
| 9 | 2013 | 146 | |
| 10 | 2021 | 143 | |
| 11 | 2019 | 131 | |
| 12 | 2016 | 124 | |
| 13 | 2021 | 119 | |
| 14 | 2019 | 114 | |
| 15 | 2013 | 92 | |
| 16 | 2017 | 85 | |
| 17 | 2019 | 83 | |
| 18 | 2017 | 79 | |
| 19 | 2016 | 76 | |
| 20 | 2019 | 64 |
About Lu Si
Lu Si is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Biomedical Engineering and Ophthalmology, having authored 212 papers that have together received 6.1k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (44 papers), Cancer Immunotherapy and Biomarkers (35 papers), Melanoma and MAPK Pathways (35 papers), Renal cell carcinoma treatment (12 papers), Optical Polarization and Ellipsometry (10 papers), Bladder and Urothelial Cancer Treatments (8 papers), MicroRNA in disease regulation (4 papers) and Ocular Oncology and Treatments (3 papers). The work is most often cited by research in Oncology (2.2k citations), Molecular Biology (1.1k citations), Cancer Research (185 citations), Ophthalmology (102 citations) and Pulmonary and Respiratory Medicine (258 citations). Lu Si has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Jun Guo, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Lili Mao, Yan Kong, Jie Dai, Bin Lian, Bixia Tang and Xieqiao Yan. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Clinical Cancer Research, BMC Cancer and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.